Details of Drug

Drug General Information (ID: D1435)
Drug Name	Sacituzumab govitecan
Drug Type	Monoclonal antibody
Drug Synonymous	Sacituzumab govitecan; 1491917-83-9; UNII-M9BYU8XDQ6; hRS 7SN38; hRS7-SN38; Sacituzumab govitecan [USAN]; IMMU 132; IMMU-132; Satralizumab linker; sacituzumab-govitecan; M9BYU8XDQ6; EX-A4354; UNII-DA64T2C2IO component ULRUOUDIQPERIJ-PQURJYPBSA-N; UNII-SZB83O1W42 component ULRUOUDIQPERIJ-PQURJYPBSA-N Click to Show/Hide
Therapeutic Class	Antineoplastics
Structure
Structure	3D Structure		2D Structure
Formula	C76H104N12O24S
InChI	InChI=1S/C76H104N12O24S/c1-3-55-56-37-54(89)16-17-61(56)83-68-57(55)43-87-63(68)38-59-58(71(87)95)45-110-74(99)76(59,4-2)112-75(100)111-44-50-10-14-52(15-11-50)81-70(94)62(7-5-6-18-77)82-66(91)47-109-46-65(90)79-19-21-101-23-25-103-27-29-105-31-33-107-35-36-108-34-32-106-30-28-104-26-24-102-22-20-86-42-53(84-85-86)40-80-69(93)51-12-8-49(9-13-51)41-88-67(92)39-64(72(88)96)113-48-60(78)73(97)98/h10-11,14-17,37-38,42,49,51,60,62,64,89H,3-9,12-13,18-36,39-41,43-48,77-78H2,1-2H3,(H,79,90)(H,80,93)(H,81,94)(H,82,91)(H,97,98)/t49?,51?,60-,62-,64?,76-/m0/s1
InChIKey	ULRUOUDIQPERIJ-PQURJYPBSA-N
Canonical SMILES	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)OC(=O)OCC5=CC=C(C=C5)NC(=O)[C@H](CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN6C=C(N=N6)CNC(=O)C7CCC(CC7)CN8C(=O)CC(C8=O)SC[C@@H](C(=O)O)N)C2=NC9=C1C=C(C=C9)O
External Link
External Link	Pubchem ID	91668186

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM004 Affected intra/extra-hepatic metabolism AM006 Pharmacodynamic additive effects AM007 Pharmacodynamic antagonistic effects BM019 UGT inhibition BM023 UGT induction BM043 Additive immunosuppressive effects BM044 Additive myelosuppressive effects BM107 Attenuated pharmacological effects (Unspecific) BM109 Increased risk of other adverse reactions (Unspecific)
Relation Graph

Full list of drugs interacting with Sacituzumab govitecan
Affected intra/extra-hepatic metabolism
	UGT inhibition					Drug Num: 10
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0116		Atazanavir	C38H52N6O7	148192	Major		Inter Info	[8], [7]
D0409		Dacomitinib	C24H25ClFN5O2	11511120	Major		Inter Info	[8], [7]
D0699		Fostamatinib	C23H26FN6O9P	11671467	Major		Inter Info	[8], [7]
D0715		Gemfibrozil	C15H22O3	3463	Major		Inter Info	[8], [7]
D0799		Indinavir	C36H47N5O4	5362440	Major		Inter Info	[8], [7]
D1136		Nilotinib	C28H22F3N7O	644241	Major		Inter Info	[8], [7]
D1232		Pazopanib	C21H23N7O2S	10113978	Major		Inter Info	[8], [7]
D1387		Regorafenib	C21H15ClF4N4O3	11167602	Major		Inter Info	[8], [7]
D1432		Rucaparib	C19H18FN3O	9931954	Major		Inter Info	[8], [7]
D1497		Sorafenib	C21H16ClF3N4O3	216239	Major		Inter Info	[8], [7]
	UGT induction					Drug Num: 15
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0095		Apalutamide	C21H15F4N5O2S	24872560	Major		Inter Info	[7]
D0194		Bosentan	C27H29N5O6S	104865	Major		Inter Info	[7]
D0255		Carbamazepine	C15H12N2O	2554	Major		Inter Info	[7]
D0697		Fosphenytoin	C16H15N2O6P	56339	Major		Inter Info	[7]
D1099		Nafcillin	C21H22N2O5S	8982	Major		Inter Info	[7]
D1128		Nevirapine	C15H14N4O	4463	Major		Inter Info	[7]
D1265		Phenobarbital	C12H12N2O3	4763	Major		Inter Info	[7]
D1283		Phenytoin	C15H12N2O2	1775	Major		Inter Info	[7]
D1302		Pitolisant	C17H26ClNO	9948102	Major		Inter Info	[7]
D1340		Primidone	C12H14N2O2	4909	Major		Inter Info	[7]
D1400		Rifampicin	C43H58N4O12	135398735	Major		Inter Info	[19], [20], [7]
D1415		Ritonavir	C37H48N6O5S2	392622	Major		Inter Info	[7]
D0601		Eslicarbazepine	C15H14N2O2	9881504	Major		Inter Info	[7]
D1592		Tipranavir	C31H33F3N2O5S	54682461	Major		Inter Info	[7]
D0953		Lorlatinib	C21H19FN6O2	71731823	Moderate		Inter Info	[11], [9], [36]
Pharmacodynamic additive effects
	Additive immunosuppressive effects					Drug Num: 24
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0023		Adalimumab	NA	NA	Major		Inter Info	[1], [2], [3], [4], [5], [6]
D0304		Certolizumab pegol	NA	NA	Major		Inter Info	[1], [5], [6]
D0614		Etanercept	NA	NA	Major		Inter Info	[1], [2], [3], [4], [5], [6]
D0661		Fingolimod	C19H33NO2	107970	Major		Inter Info	[14]
D0736		Golimumab	NA	NA	Major		Inter Info	[1], [2], [3], [4], [5], [6]
D0802		Infliximab	NA	NA	Major		Inter Info	[1], [2], [3], [4], [5], [6]
D0900		Leflunomide	C12H9F3N2O2	3899	Major		Inter Info	[15], [16]
D1111		Natalizumab	NA	NA	Major		Inter Info	[17]
D1211		Ozanimod	C23H24N4O3	52938427	Major		Inter Info	[9], [18]
D1474		Siponimod	C29H35F3N2O3	44599207	Major		Inter Info	[11], [21]
D1556		Teriflunomide	C12H9F3N2O2	54684141	Major		Inter Info	[15], [16]
D0032		Alefacept	NA	NA	Moderate		Inter Info	[22], [23], [24]
D0085		Anakinra	C20H23N5O7S2	146171046	Moderate		Inter Info	[26], [27], [28]
D0246		Canakinumab	NA	NA	Moderate		Inter Info	[26], [27], [28]
D0443		Denosumab	NA	NA	Moderate		Inter Info	[29]
D0499		Dimethyl fumarate	C6H8O4	637568	Moderate		Inter Info	[30]
D0553		Efalizumab	NA	NA	Moderate		Inter Info	[31]
D1162		Ocrelizumab	NA	NA	Moderate		Inter Info	[37]
D1174		Omacetaxine mepesuccinate	C29H39NO9	285033	Moderate		Inter Info	[38]
D1403		Rilonacept	NA	NA	Moderate		Inter Info	[26], [27], [28]
D0507		Diroximel fumarate	C11H13NO6	73330464	Moderate		Inter Info	[30]
D1085		Monomethyl fumarate	C5H6O4	5369209	Moderate		Inter Info	[30]
D1610		Topotecan	C23H23N3O5	60700	Moderate		Inter Info	[41]
D1671		Ustekinumab	NA	NA	Moderate		Inter Info	[42]
	Additive myelosuppressive effects					Drug Num: 5
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0348		Cladribine	C10H12ClN5O3	20279	Major		Inter Info	[9], [10]
D0433		Deferiprone	C7H9NO2	2972	Major		Inter Info	[11], [12], [13]
D0845		Irinotecan	C33H38N4O6	60838	Major		Inter Info	[7]
D0846		Irinotecan (liposomal)	C33H38N4O6	60838	Major		Inter Info	[7]
D0033		Alemtuzumab	NA	NA	Moderate		Inter Info	[25]
	Increased risk of other adverse reactions (Unspecific)					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0789		Idelalisib	C22H18FN7O	11625818	Moderate		Inter Info	[35]
Pharmacodynamic antagonistic effects
	Attenuated pharmacological effects (Unspecific)					Drug Num: 3
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0659		Filgrastim	NA	NA	Moderate		Inter Info	[32], [33], [34]
D1235		Pegfilgrastim	C27H46N4O19	70683024	Moderate		Inter Info	[39], [40]
D1446		Sargramostim	NA	NA	Moderate		Inter Info	[32], [33], [34]

References
1	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
2	Product Information. Enbrel (etanercept). Wyeth-Ayerst Laboratories, Philadelphia, PA.
3	Product Information. Humira (adalimumab). Abbott Pharmaceutical, Abbott Park, IL.
4	Product Information. Remicade (infliximab). Centocor Inc, Malvern, PA.
5	Product Information. Simponi (golimumab). Centocor Inc, Malvern, PA.
6	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. ".
7	Product Information. Trodelvy (sacituzumab govitecan). Immunomedics, Morris Plains, NJ.
8	Product Information. Nexavar (sorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
9	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
10	Product Information. Leustatin (cladribine). Ortho Biotech Inc, Raritan, NJ.
11	Cerner Multum, Inc. "Australian Product Information.".
12	Product Information. Ferriprox (deferiprone). ApoPharma USA Inc, Rockville, MD.
13	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports."
14	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
15	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
16	Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
17	Product Information. Tysabri (natalizumab). Elan Pharmaceutical/Athena Neurosciences Inc, South San Francisco, CA.
18	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
19	Canadian Pharmacists Association.
20	Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
21	Product Information. Mayzent (siponimod). Novartis Pharmaceuticals, East Hanover, NJ.
22	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
23	Product Information. Amevive (alefacept). Biogen, Cambridge, MA.
24	Product Information. Lonsurf (tipiracil-trifluridine). Taiho Oncology, Inc., Princeton, NJ.
25	Product Information. Campath (alemtuzumab) Berlex, Richmond, CA.
26	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
27	Product Information. Ilaris (canakinumab). Novartis Pharmaceuticals, East Hanover, NJ.
28	Product Information. Kineret (anakinra). Amgen, Thousand Oaks, CA.
29	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
30	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
31	Product Information. Raptiva (efalizumab). Genentech, South San Francisco, CA.
32	Product Information. Granix (tbo-filgrastim). Teva Pharmaceuticals USA, North Wales, PA.
33	Product Information. Leukine (sargramostim). Immunex Corporation, Seattle, WA.
34	Product Information. Stemgen (ancestim) Amgen, Thousand Oaks, CA.
35	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
36	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
37	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
38	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
39	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
40	Product Information. Neulasta (pegfilgrastim). Amgen, Thousand Oaks, CA.
41	Product Information. Hycamtin (topotecan). SmithKline Beecham, Philadelphia, PA.
42	Product Information. Stelara (ustekinumab). Centocor Inc, Malvern, PA.

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence